Inhibition of malignant angiogenesis

Cancer Treatment Reviews

Volumn 23, Issue 4, 1997, Pages 263-286

  Jekunen, A P ^a   Kairemo, K J A ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; 8,9 DIHYDROXY 7 METHYLBENZO[B]QUINOLIZINIUM BROMIDE; ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; BLEOMYCIN; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GOLD DERIVATIVE; GROWTH FACTOR RECEPTOR; HEPARIN DERIVATIVE; INTERFERON; LAMININ; LIPID; MINOCYCLINE; PROTEIN KINASE INHIBITOR; PROTEINASE INHIBITOR; RETINOID; ROQUINIMEX; SURAMIN; TAMOXIFEN; THROMBOSPONDIN; UNINDEXED DRUG; VASCULOTROPIN; VITAMIN D;

ANGIOGENESIS; BASEMENT MEMBRANE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER; CANCER GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; EXTRACELLULAR MATRIX; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LYMPHOCYTOPENIA; METASTASIS; NEUROPATHY; NONHUMAN; PLASMINOGEN ACTIVATION; PROGNOSIS; REVIEW; THROMBOCYTOPENIA; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 0030724588     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(97)90014-1     Document Type: Article

References (135)

1. Bicknell, R. (1994) Angiogenesis. Ann. Oncol. (Suppl.): 4: 45-50.
2. Le Querrec, A., Duval, D. & Tobelem, G. (1993) Tumour angiogenesis. Baillieres Clin. Haematol. 6: 711-730.
3. Billington, D.C. (1991) Angiogenesis and its inhibition: potential new therapies in oncology and non-neoplastic diseases. Drug Des. Discov. 8: 3-35.
4. Kerbel, R.S. (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13: 31-6.
5. Folkman, J. (1990) What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82: 4-6.
6. Liotta, L., Kleinerman, J. & Saldel, G. (1974) Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 34: 997-1004.
7. Starkey, J.R., Crowlew, P.K. & Taubenberger, S. (1988) MAs-cell deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int. J. Cancer 42: 48-52.
8. Gross, J.L., Herblin, W.F., Dusak, B.A. et al. (1993) Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J. Natl. Cancer Inst. 85: 121-131.
9. Ausprunk, D.H. & Folkman, J. (1977) Migration and proliferation of endothelial cells in preformed and newly formed vessels during angiogenesis. Microvasc. Res. 14: 53-65.
10. Denekamp, J. (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 90: 267-282.
11. Srivastava, A., Laidler, P., Davies, R.P., Horan, K. & Hughes, L.E. (1988) The prognostic significance of tumor vascularity in intermediate thickness (0.76-4.0 mm thick) skin melanomas: a quantitative histologic study. Am. J .Pathol. 133: 419-423.
12. Macchiariarini, P., Fontanini, G., Hardin, M.J., Squartini, F. & Angeletti, C.A. (1991) Relation of neovasculature to metastasis of non-small-cell lung cancer. Lancet 340: 145-146.
13. Weidner, N., Carrol, P.R., Flax, J., Blumenfeld, W. & Folkman, J. (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143: 401-409.
14. Weidner, N., Semple, J.P., Welch, W.R. & Folkman, J. (1991) Tumor angiogenesis and metastasis - correlation in invasive breast cancer. N. Engl. J. Med. 324: 1-8.
15. Ogawa, Y.-S., Chung, Y.-S., Nakata, B. et al. (1995) Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen. Br. J. Cancer 71: 1297-1301.
16. Weidner, N., Folkman, J., Pozza, F. et al. (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast cancer. J. Natl. Cancer Inst. 84: 1875-1887.
17. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W. & Ullrich, A. (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579.
18. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S. & Ferrara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844.
19. Ingber, D., Fujita, T., Kishimoto, S. et al. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348: 555-557.
20. O'Reilly, M.S., Holmgren, L., Shing, Y. et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediated the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
21. Gimbrone, M.A. Jr. (1976) Culture of vascular endothelium. Prog. Hemostasis Thromb. 3: 1-28.
22. Kern, P.A., Knedler, A. & Eckel, R.H. (1983) Isolation and culture of microvascular endothelium from human adipose tissue. J. Clin. Invest. 71: 1822-1829.
23. Tannock, I. (1970) Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res. 30: 2470-2474.
24. Lee, K.E., Iwamura, M. & Cockett, A.T. (1990) Cortisone inhibition of tumor angiogenesis measured by a quantitative colorimetric assay in mice. Cancer Chemother. Pharmacol. 26: 461-463.
25. Nguyen, M., Shing, Y. & Folkman, J. (1994) Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc. Res. 47: 31-40.
26. Passaniti, A., Taylor, R.M., Pili, R. et al. (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67: 519-528.
27. Foschi, D., Castoldi, L., Corsi, F., Radaelli, E. & Trabucchi, E. (1994) Inhibition of inflammatory angiogenesis in rats by loco-regional administration of hydrocortisone and protamine. Agents Actions 42: 40-43.
28. Plate, K.H., Breier, G., Millauer, B., Ullrich, A. & Risau, W. (1993) Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 53: 5822-5827.
29. Shokravi, M.T., Marcus, D.M., Alroy, J., Egan, K., Saornil, M.A. & Albert, D.M. (1995) Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest. Ophthalmol. Vis. Sci. 36: 83-87.
30. Gimbrone, M.A. Jr., Cotran, R.S., Leapman, S.B. & Folkman, J. (1974) Tumor growth and neovascularization: an experimental model using rabbit cornea. J. Natl. Cancer Inst. 52: 413-427.
31. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285: 1182-1186.
32. Greenblatt S, Shuki I. (1968) Angiogenesis. J. Natl. Cancer Inst. 41: 111-124.
33. Auerbach, R., Auerbach, W. & Polakowski, I. (1991) Assays for angiogenesis: a review. Pharmacol. Ther. 51: 1-11.
34. Moses, M.A., Sudhalter, J. & Langer, R. (1990) Identification of an inhibitor of neovascularization from cartilage. Science 248: 1408-1410.
35. Stetler-Stevenson, W.G., Krutzsch, H.C. & Liotta, L.A. (1992) TIMP-2: identification and characterization of a new member of the metalloproteinase inhibitor family. Matrix Supp. 299-306.
36. Murphy, A.N., Unsworth, E.J. & Stetler-Stevenson, W.G. (1993) Tissue inhibitor of metallo-proteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell Physiol. 157: 351-358.
37. Brem, H. & Folkman, J. (1975) Inhibition of angiogenesis mediated by cartilage. J. Exp. Med. 141: 427-439.
38. Murray, J.B., Allison, K., Sudhalter, J. & Langer, R. (1986) Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. J. Biol. Chem. 261: 4154-4159.
39. Sipos, E.P., Tamargo, R.J., Weingart, J.D. & Brem, H. (1994) Inhibition of tumour angiogenesis. Ann. N. Y. Acad. Sci. 732: 263-72.
40. Golub, L.M., Lee, H.M., Lehrer, G. et al. (1983) Minocycline reduced gingival collagenolytic activity during diabetes. J. Periodontal Res. 18: 516-526.
41. Greenwald, R.A., Golub, L.M., Lavietes, B. et al. (1987) Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J. Rheumatol. 14: 28-32.
42. Schlondorff, D. & Satriano, J. (1985) Interactions with calmodulin: potential mechanism for some inhibitory actions of tetracyclines and calcium channel blockers. Biochem. Pharmacol. 34: 3391-3393.
43. Tamargo, R.J., Bok, R.A. & Brem, H. (1991) Angiogenesis inhibition by minocycline. Cancer Res. 51: 672-675.
44. Tokida, Y., Aratani, Y., Morita, A. & Kitagawa, Y (1990) Production of two variant laminin forms by endothelial cells and shift of their relative levels by angiostatic steroids. J. Biol. Chem. 265: 18123-18129.
45. Sakamoto, N., Iwahana, M., Tanaka, N.G. & Osada, Y (1991) Inhibition of angiogenesis and tumour growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res. 51: 903-906.
46. Missirlis, E., Karakiulakis, G. & Maragoudakis, M.E. (1990) Antitumor effect of GPA1734 in rat Walker 256 carcinoma. Invest. New Drugs 8: 145-147.
47. Ichikawa, T., Lamb, J.C., Christensson, P.I., Hartley-Asp, B. & Isaacs, J.T. (1992) The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res. 52: 3022-3028.
48. Borgstrom, P., Torres-Filho, I.P., Vajkoczy, P., Strandgarden, K., Polacek, J. & Hartley-Asp, B. (1994) The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Cancer Chemother. Pharmacol. 34: 280-286.
49. Lotan, R. (1991) Retinoids as modulators of tumor cells invasion and metastasis. Semin. Cancer Biol. 2: 197-208.
50. Oikawa, T., Yoshida, Y., Shimamura, M., Ashino-Fuse, H., Iwaguchi, T. & Tominaga, T. (1991) AntiTumour effect of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene. Anticancer Drugs 2: 475-480.
51. Pienta, K.J., Nguyen, N.M. & Lehr, J.E. (1993). Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res. 53: 224-266.
52. Halaban, R., Langdon, R., Birchall, C. et al. (1988) Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J. Cell Biol. 107: 1611-1617.
53. Westermark, B., Johnsson, A., Paulsson, Y et al. (1986) Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc. Natl. Acad. Sci. USA 83: 7179-7200.
54. Rak, J.W., Hegmann, E.J., Lu, C. & Kerbel, R.S. (1994) Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J. Cell Physiol. 159: 245-255.
55. Arteaga, C.L., Hurd, S.D., Winnier, A.R., Johnson, M.D., Fendly, B.M., & Forbes, J.T. (1993) Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J. Clin. Invest. 92: 2569-2576.
56. Morrison, R.S., Giordano, S., Yamaguchi, F., Hendrickson, S., Berger, M.S. & Palczewski, K. (1993) Basic fibroblast growth factor expression is required for clonogenic growth of human glioma cells. J. Neurosci. Res. 34: 502-529.
57. Bagavandoss, P. & Wilks, J.W. (1990) Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem. Biophys. Res. Commun. 170: 867-872.
58. Rastinejad, F., Polverini, P.J. & Bouck, N.P. (1989) Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56: 345-355.
59. Oikawa, T., Hasegawa, M., Morita, I. et al. (1992) Effect of 15-deoxyspergualin, a microbial angiogenesis inhibitor, on the biological activities of bovine vascular endothelial cells. Anticancer Drugs 3: 293-299.
60. Oikawa, T., Ito, H., Ashino, H. et al. (1993) Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis. Eur. J. Pharmacol. 241: 221-227.
61. Oikawa, T., Hasegawa, M., Shimamura, M., Ashino, H., Murota, S. & Morita, I. (1991) Eponemycin, a novel antibiotic, is a highly powerful angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 181: 1070-1076.
62. Yanase, T., Tamura, M., Fujita, K., Kodama, S. & Tanaka, K. (1993) Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res. 53: 2566-70.
63. Oikawa, T., Hirotani, K., Ogasawara, H. et al. (1990) Inhibition of angiogenesis by bleomycin and its copper complex. Chem. Pharm. Bull Tokyo 38: 1790-1792.
64. Maragoudakis, M.E., Peristeris, P., Missirlis, E., Aletras, A., Andriopoulou, P. & Haralabopoulos, G. (1994) Inhibition of angiogenesis by anthracyclines and titanocene dichloride. Ann. N. Y. Acad. Sci. 732: 280-293.
65. Ito, K., Abe, T., Tomita, M. et al. (1993) Anti-angiogenic activity of arachidonic acid metabolism inhibitors in angiogenesis model systems involving human microvascular endothelial cells and neovascularization in mice. Int. J. Cancer 55: 660-666.
66. Candal, F.J., Bosse, D.C., Vogler, W.R. & Ades, E.W. (1994) Inhibition of induced angiogenesis in a human microvascular endothelial cell line by ET-18-OCH3. Cancer Chemother. Pharmacol. 34: 175-178.
67. Vogel, T., Guo, N.H., Guy, R. et al. (1994) Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J. Cell Biochem. 54: 299-308.
68. Vogel, T., Guo, N.H., Krutzsch, H.C. et al. (1993) Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J. Cell Biochem. 53: 74-84.
69. Jakobson, A.M. & Hahnenberger, R. (1991) Antiangiogenic effect of heparin and other sulphated glycosaminoglycans in the chick embryo chorioallantoic membrane. Pharmacol. Toxicol. 69: 122-126.
70. Hahnenberger, R. & Jakobson, A.M. (1993) Antiangiogenic effect of sulphated and nonsulphated glycosaminoglycans and polysaccharides in the chick embryo chorioallantoic membrane. Glycoconj.-J. 8: 350-353.
71. Zugmaier, G., Lippman, M.E. & Wellstein, A. (1992) Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J. Natl. Cancer Inst. 84: 1716-1724.
72. Nguyen, N.M., Lehr, J.E., & Pienta, K.J. (1993) Pentosan inhibits angiogenesis in vitro and suppresses prostate tumour growth in vivo. Anticancer Res. 13: 2143-2147.
73. Wellstein, A., Zugmaier, G., Califano, J.A. 3rd, Kern, F., Paik, S. & Lippman, M.E. (1991) Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J. Natl. Cancer Inst. 83: 716-720.
74. Thorpe, P.E., Derbyshire, E.J., Andrade, S.P. (1993). Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. Cancer Res. 53: 3000-3007.
75. Zhang, Y., Deng, Y., Luther, T. et al. (1994) Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J. Clin. Invest. 94: 1320-1327.
76. Michaud, M. & Poyet, P. (1994) Control of the expression of thrombospondin 1 in human breast cancer cell lines. Anticancer Res. 14: 1127-1131.
77. Iruela-Arispe, M.L., Bornstein, P. & Sage, H. (1991) Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc. Natl. Acad. Sci. USA 88: 5026-5030.
78. DiPietro, L.A., Nebgen, D.R. & Polverini, P.J. (1994) Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis. J. Vasc. Res. 31: 178-185.
79. Salnikow, K., Cosentino, S., Klein, C. & Costa, M. (1994) Loss of thrombospondin transcriptional activity in nickel-transformed cells. Mol. Cell Biol. 14: 851-858.
80. Fotsis, T., Zhang, Y., Pepper, M.S. et al. (1994) The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368: 237-239.
81. Clapp, C., Martial, J.A., Guzman, R.C., Rentier-Delure, F. & Weiner, R. (1993). The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133: 1292-1299.
82. Ferrara, N., Clapp, C. & Weiner, R. (1991) The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129: 896-900.
83. D'Angelo, G., Struman, I., Martial, J. & Weiner, R.I. (1995) Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc. Natl. Acad. Sci. USA 92: 6374-6378.
84. Cook, S.J. & McCormick, F. (1993) Inhibition by cAMP of Ras-dependent activation of Raf. Science 262: 1069-1072.
85. Ashino-Fuse, H., Takano, Y., Oikawa, T., Shimamura, M. & Iwaguchi, T. (1989) Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int. J. Cancer 44: 859-864.
86. Jikihara, H., Terada, N., Yamamoto, R. et al. (1992) Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endometrial cancer. Am. J. Obstet. Gynecol. 167: 207-211.
87. Kono, S., Rao, J.S., Bruner, J.M. & Sawaya, R. (1994) Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J. Neuropathol. Exp. Neurol. 53: 256-262.
88. Pyke, C., Kristensen, P., Ralfkiaer, E., Eriksen, J. & Dano, K. (1991) The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 51: 4067-4071.
89. Grondahl-Hansen, J., Christensen, I.J., Rosenquist, C. et al. (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53: 2513-2521.
90. Towle, M.J., Lee, A., Maduakor, E.G., at al. (1993) Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res. 53: 2553-2559.
91. Lelievre, S. & Larsen, A.K. (1994) Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential. Cancer Res. 54: 3993-3997.
92. Braddock, P.S., Hu, D.E., Fan, T.P., Stratford, I.J., Harris, A.L. & Bicknell, R. (1994) A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Brit. J. Cancer 69: 890-898.
93. Oikawa, T., Shimamura, M., Ashino, H. et al. (1992) Inhibition of angiogenesis by staurosporine, a potent protein kinase inhibitor. J. Antibiot. Tokyo 45: 1155-1160.
94. Oikawa, T., Ashino, H., Shimamura, M. et al. (1993) Inhibition of angiogenesis by erbstatin, an inhibitor of tyrosine kinase. J. Antibiot. Tokyo 46: 785-790.
95. Koroma, B.M. & deJuan, E. Jr. (1994) Phosphotyrosine inhibition and control of vascular endothelial cell proliferation by genistein. Biochem. Pharmacol. 48: 809-818.
96. Fotsis, T., Pepper, M., Adlercreutz, H. et al. (1993) Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc. Natl. Acad. Sci. USA 90: 2690-2694.
97. Folkman, J. (1995) Clinical application of research on angiogenesis. N. Engl. J. Med. 333: 1757-1763.
98. Kohn, E.C., Alessandro, R., Spoonster, J., Wersto, R.P. & Liotta, L.A. (1995) Angiogenesis: role of calcium-mediated signal transduction. Proc. Natl. Acad. Sci. USA 92: 1307-1311.
99. Oikawa, T., Ashino-Fuse, H., Shimamura, M., Koide, U. & Iwaguchi, T. (1990) A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett. 51: 181-186.
100. Saura, R., Matsubara, T. & Mizuno, K. (1994) Inhibition of neovascularization in vivo by gold compounds. Rheumatol. Int. 14: 1-7.
101. Hawkins, M.J. (1995) Clinical trials of antiangiogenic agents. Curr. Opin. Oncol. 7: 90-93.
102. Lippman, S.M., Parkinson, D.R., Itri, L.M. et al. (1992) 13-cis-retinoic acid and Interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J. Natl. Cancer Inst. 84: 235-241.
103. Majewski, S., Marczak, M., Szmurlo, A., Jablonska, S. & Bollag, W. (1995) Retinoids, Interferon alpha, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett. 89: 117-124.
104. Brem, H., Gresser, I., Grosfeld, J. & Folkman, J. (1993) The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J. Pediatr. Surg. 28: 1253-1257.
105. Norrby, K. (1994) Evidence of specificity in the action of angiogenesis antagonists. Int. J. Microcirc. Clin. Exp. 14: 226-232.
106. D'Amato, R.J., Loughnan, M.S., Flynn, E. & Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91: 4082-4085.
107. Merwin, J.R., Lynch, M.J., Madri, J.A., Pastan, I. & Siegall, C.B. (1992) Acidic fibroblast growth factor-Pseudomonas exotoxin chimeric protein elicits antiangiogenic effects on endothelial cells. Cancer Res. 52: 4995-5001.
108. Folkman, J. & Shing, Y. (1992) Control of angiogenesis by heparin and other sulfated polysaccharides. Adv. Exp. Med. Biol. 313: 355-364.
109. Wilks, J.W. (1992) Steroids inhibitors of angiogenesis. In: Alexander, N.J. & d'Arcangues, C., eds, Steroid Hormones and Uterine Bleeding. Washington DC: American Association for the Advancement of Science, pp. 159-169.
110. Myers, C., Cooper, M., Stein, C. et al. (1992) Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostatate cancer. J. Clin. Oncol. 10: 881-889.
111. La Rocca, R., Cooper, M. & Stein, C. (1992) A pilot study of suramin in the treatment of progressive refractory follicular lymphomas. Ann. Oncol. 3: 371.
112. Stein, C.A., La Rocca, R.V. & Thomas, R. (1989) Suramin: an anticancer drug with a unique mechanism of action. J. Clin. Oncol. 7: 499-508.
113. Reed, E., Cooper, M.R. & La Rocca, R.V. (1992) Suramin in advanced platinum-resistant ovarian cancer. Eur. J. Cancer 28A: 864-866.
114. Nakamura, S., Sakurada, S., Salahuddin, S.Z. et al. (1992) Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science 255: 1437-1440.
115. Eckhardt, S.G., Burris, H.A., Eckhardt, J.R. et al. (1994) Phase I assessment of the novel angiogenesis inhibitor DS4152 (tecogalan sodium). Proc. Am. Soc. Clin. Oncol. 13: 55.
116. Ingber, D., Fujita, T., Kishimoto, S. et al. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348: 555-557.
117. Takamiya, Y., Friedlander, R.M., Brem, H., Malick, A., & Martuza, R.L. (1993) Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-470. J. Neurosurg. 78: 470-476.
118. Zukiwski, A., Gutterman, J., Bui, C. et al. (1994) Phase I trial of the angiogenesis inhibitor TNP-470 (AGM-1470) in patients with androgen independent prostate cancer. Proc. Am Soc. Clin. Oncol. 13: 252.
119. Davies, B., Brown, P.D., East, N., Crimmin, M.J. & Balkwill, F.R. (1993) A synthetic matrix metalloprotease inhibitor decreases tumour burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 53: 2087-2091.
120. White, C.W., Sondheimer, H.M., Crouch, E.G., Wilson, H. & Fan, L.L. (1989) Therapy of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N. Engl. J. Med. 320: 1197-1200.
121. Fung, W.E. (1991) Interferon alpha 2 a for treatment of age-related macular degeneration. Am. J. Ophthalmol. 112 :349-350.
122. Brouty-Boye, D. & Zetter, B. (1980) Inhibition of endothelial cell proliferation by gamma interferon. J. Cell Biol. 104: 689-696.
123. Sharpe, R.J., Byers, H.R., Scott, C.F., Bauer, S.I. & Maione, T.E. (1990) Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J. Natl. Cancer Inst. 82: 848-853.
124. Staddon, A., Henry, D. & Bonnem, A. (1994) A randomized dose dfinding study of recombinant platelet factor 4 in cutaneous AIDS-related Kaposi's sarcoma. Proc. Am. Soc. Clin. Oncol. 13: 50.
125. Belman, N., Lipton, A., Harvey, H., Kambic, K., Bonnem, E. & Visconti, E. (1994). rhuPF4-phase I study of an angiogenesis inhibitor in metastatic colon cancer. Proc. Am. Soc. Clin. Oncol. 13:221.
126. Davies, B., Brown, P.D. & East, N. (1993) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolong survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 53: 2087-2091.
127. Bengtsson, M., Simonsson, B. & Carlsson, K. et al. (1992) Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator linomide after bone marrow transplantation. Transplantation 53: 882-888.
128. Hellman, K., Gilbert, J. & Evans, M. (1987) Effect of razoxane on metastases from colorectal cancer. Clin. Exp. Metastasis 5: 3-8.
129. Rofstad, E.K. (1984) Growth and vascular structure of human melanoma xenografts. Cell Tissue Kinet. 17: 91-101.
130. Blood, C.H. & Zetter, B.R. (1990) tumour interactions with the vasculature: angiogenesis and tumour metastasis. Biochim. Biophys. Acta 1032: 89-118.
131. Gasparini, G. & Harris, A.L. (1994) Does improved control of tumor growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells? Eur. J. Cancer 30A: 201-206.
132. Cole, E., & Kohn, E.G. (1994) Calcium mediated signal transduction: biology, biochemistry and therapy. Cancer Met Rev. 13: 31-44.
133. Kohn, E.G., Reed, E. & Sarosy, G. (1996) Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res. 56: 569-573.
134. Hayes, D.F. (1994) Angiogenesis and breast cancer. Hematol. Oncol. Clin. North. Am. 8: 51-71.
135. Diaz-Flores, L., Gutierrez, R. & Varela, H. (1994) Angiogenesis: an update. Histol. Histopathol. 9: 807-843.